MedTrace Logo

Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome

NCT01291199 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2011-02-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.

Conditions

  • Raynaud Syndrome

Interventions

DRUG

vardenafil

10 mg p.o. bid for 6 weeks

DRUG

Placebo

Placebo p.o. 6 weeks bid

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Stephan Rosenkranz, MD · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-08-31
Completion
2010-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291199 on ClinicalTrials.gov